Tariquidar

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

A potent, specific P-gp inhibitor with Kd of 5.1 nM.

A potent, specific P-gp inhibitor with Kd of 5.1 nM; potentiates the cytotoxicity of several drugs including doxorubicin, paclitaxel, etoposide, and vincristine in a panel of human MDR cell lines at 25-80 nM; exhibits potent i.v. and p.o. activity without apparently enhancing the plasma pharmacokinetics of paclitaxel or the toxicity of coadministered drugs.Breast Cancer Phase 2 Discontinued

XR 9576;XR-9576;XR9576

Membrane Transporter/Ion Channel

P-glycoprotein

P-gp(P-glycoprotein)

Cancer

Breast Cancer

206873-63-4

646.73

C38H38N4O6

>98% (HPLC)

DMSO: ≥ 100 mg/mL

COC1=CC2=C(CN(CCC3=CC=C(NC(=O)C4=C(NC(=O)C5=CC6=CC=CC=C6N=C5)C=C(OC)C(OC)=C4)C=C3)CC2)C=C1OC |c:17,26,28,31,40,43,49,t:2,4,10,12,22,24,34|

3-Quinolinecarboxamide, N-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]-

(-20℃)

With Ice Pack

≥ 2 years